Summary & Overview
HCPCS S3722: Dose Optimization by AUC Analysis for Infusional 5-Fluorouracil
HCPCS Level II code S3722 denotes dose optimization by area under the curve (AUC) analysis for infusional 5-fluorouracil, a pharmacokinetic service used to tailor dosing of continuous 5-FU chemotherapy. This testing service is clinically important because AUC-guided dosing can reduce toxicity and help achieve therapeutic exposures for cytotoxic chemotherapy agents administered by infusion. Nationally, pharmacokinetic dose adjustments for 5-FU are relevant to oncology practices, hospital outpatient infusion departments, and clinical laboratories supporting chemotherapy monitoring.
Key payers considered in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the service represented by S3722, the typical sites of service where it is performed, and the clinical rationale for AUC-based dosing. The publication includes benchmarks and policy-related context where available, outlines common billing considerations, and highlights how payers approach coverage and coding for pharmacokinetic dose optimization services. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3722 describes dose optimization by area under the curve (AUC) analysis for infusional 5-fluorouracil. This service represents laboratory-directed pharmacokinetic assessment used to adjust dosing of continuous or infusional 5-fluorouracil based on calculated drug exposure (AUC) to optimize therapeutic effect and limit toxicity.
Service type: Pharmacokinetic dose optimization / therapeutic drug monitoring
Typical site of service: Oncology infusion center, hospital outpatient infusion clinic, or specialized clinical laboratory performing AUC analysis
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with stage III colorectal adenocarcinoma is receiving infusional 5-fluorouracil (5-FU) as part of an adjuvant chemotherapy regimen. The oncology team orders therapeutic drug monitoring using area under the curve (AUC) analysis to optimize the continuous infusion dose of 5-FU after the first infusion cycle. Peripheral or central venous blood samples are collected at specified time points during the infusion and sent to a clinical pharmacology laboratory. The laboratory performs plasma 5-FU concentration measurements and calculates AUC to determine exposure. Results are communicated to the treating medical oncologist, who documents dose adjustments in the electronic medical record and issues an updated infusion plan for the next cycle to improve efficacy and reduce toxicity risk.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component if the laboratory or facility bills the technical component separately. |
TC | Technical component | Use when reporting only the technical component (laboratory processing and instrumentation) separate from professional interpretation. |